Showing 1 - 20 results of 107 for search '(( 10 ((we decrease) OR (((_ decrease) OR (mean decrease)))) ) OR ( 50 mg decrease ))~', query time: 0.71s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

    Published 2020
    “…WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”
  11. 11

    Supplementary Material for: Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland by Haase C.L. (11305977)

    Published 2021
    “…Mean 7-month weight change from baseline in the full cohort was −4.1 kg (95% confidence interval: −5.0, −3.2; <i>p</i> < 0.001; −4.2%). …”
  12. 12

    Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-co... by Tadao Akizawa (316095)

    Published 2018
    “…Adverse events were observed in 30%–50% of patients (all groups). Incidence of adverse events was similar among all groups except for decreased calcium, which occurred more frequently in the evocalcet 2 mg and cinacalcet groups.…”
  13. 13
  14. 14

    Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox by Nancy F. Olivieri (6407168)

    Published 2019
    “…The primary endpoint of monitoring in iron overload, hepatic iron concentration (HIC), increased (worsened) during deferiprone monotherapy (mean 10±2–18±2 mg/g; p < 0.0003), exceeding the threshold for life-threatening complications (15 mg iron/g liver) in 50% patients. …”
  15. 15
  16. 16
  17. 17

    Zonarol suppresses DSS-induced UC in Slc:ICR mic. by Sohsuke Yamada (602944)

    Published 2014
    “…<b>B</b>) The DAI scores were dramatically increased in DSS positive control mice compared with those in the other groups of mice treated with zonarol at 10 mg/kg or 20 mg/kg or 5-ASA 50 mg/kg from day 9 to 15. …”
  18. 18
  19. 19

    Effect of phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention by Nidia D. Pucci (5631659)

    Published 2018
    “…Materials and Methods: We studied 56 patients with kidney stones <10mm. …”
  20. 20

    Supplementary Material for: Urea Reduction in Acute Kidney Injury and Mortality Risk by Chávez-Íñiguez J.S. (11189730)

    Published 2023
    “…<b><i>Methods:</i></b> Patients with AKI admitted to the Hospital Civil de Guadalajara were enrolled in this retrospective cohort study. We create 4 groups of urea reduction ratio (UXR) stratified by their decrease in urea from the highest index value in comparison to the value on day 10 (0%, 1–25%, 26–50%, and >50%), or at the time of death or discharge if prior to 10 days. …”